MNG1019
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.424
- IL6_JAK_STAT3_SIGNALING+0.386
- ALLOGRAFT_REJECTION+0.365
- OXIDATIVE_PHOSPHORYLATION+0.357
- MYC_TARGETS_V1+0.325
- ADIPOGENESIS+0.303
- PROTEIN_SECRETION+0.261
- KRAS_SIGNALING_UP+0.251
- COMPLEMENT+0.249
- WNT_BETA_CATENIN_SIGNALING+0.242
Top 10 suppressed
- G2M_CHECKPOINT-0.253
- KRAS_SIGNALING_DN-0.204
- PANCREAS_BETA_CELLS-0.168
- E2F_TARGETS-0.160
- MITOTIC_SPINDLE-0.131
- SPERMATOGENESIS-0.129
- MYC_TARGETS_V2-0.084
- INTERFERON_ALPHA_RESPONSE-0.048
- ESTROGEN_RESPONSE_EARLY-0.031
- APICAL_SURFACE-0.017
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 62BFF895-C5CC-4F59-8348-2026B659FDF5 | — | — | 0.823 |
| 2 | 0F8847C7-545C-4C3C-B3D0-0681C9480712 | — | — | 0.817 |
| 3 | BS_E3EJHXQV | low-grade glioma | — | 0.805 |
| 4 | BS_ZZMYDZJW | pilocytic astrocytoma | — | 0.803 |
| 5 | BS_BKQZ550R | pilocytic astrocytoma | — | 0.800 |
| 6 | CCA161B9-1E9A-4F8C-8144-B32B5CF76ECC | — | — | 0.800 |
| 7 | 6F4F72B3-E2B1-48DD-B9F4-C03AFCE79566 | — | — | 0.795 |
| 8 | DRR168598 | — | — | 0.795 |
| 9 | 0E9EAAED-A9A2-41E7-AC3A-49E94C933432 | — | — | 0.792 |
| 10 | 31D3488A-212B-4818-8F09-EBF1E8B135AD | — | — | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.424 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.386 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.365 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.357 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.325 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.303 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.261 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.251 | Inavolisib | — uncovered |
| COMPLEMENT | 0.249 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.242 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.241 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.239 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.234 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.215 | Idelalisib | — uncovered |
| APOPTOSIS | 0.213 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.213 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.197 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.197 | Idelalisib | — uncovered |
| PEROXISOME | 0.194 | Idelalisib | — uncovered |